This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
by Kinjel Shah
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
by Kinjel Shah
LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
by Zacks Equity Research
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
by Zacks Equity Research
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Company News for Aug 21, 2024
by Zacks Equity Research
Companies In The News Are: LLY, BA, AS, MDT.
Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly
by Zacks Equity Research
Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly have been highlighted in this Investment Ideas article.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
by Andrew Rocco
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
by Kinjel Shah
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters
by Zacks Equity Research
Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Zacks Investment Ideas feature highlights: Walmart, Cardinal Health and Eli Lilly
by Zacks Equity Research
Walmart, Cardinal Health and Eli Lilly have been highlighted in this Investment Ideas article.
Why Lilly (LLY) Might be Well Poised for a Surge
by Zacks Equity Research
Lilly (LLY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Companies Reporting Remarkable Results: WMT, LLY, CAH
by Derek Lewis
All three companies posted robust results and upped their outlooks, a bullish pairing. Is it time to buy?
What Makes Eli Lilly (LLY) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Philips (PHG) Extends Isala Partnership, Boosts Customer Base
by Zacks Equity Research
Philips (PHG) extends its partnership Isala hospital to optimize the latter's healthcare processes, expanding its customer base.
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
by Kinjel Shah
Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen
by Zacks Equity Research
Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.
Lilly (LLY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
by Kinjel Shah
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.
Wall Street Analysts See Lilly (LLY) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?
by Shaun Pruitt
As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.